Giovambattista De Sarro

Prof. Giovambattista De Sarro

orcid

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2013 in Environmental Toxicology and Pharmacology
Verified
Journal Article
Closed access
PVPasquale Ventrice
Pasquale Ventrice
DVDomenica Ventrice
Domenica Ventrice
EREmilio Russo
Emilio Russo
GSGiovambattista De Sarro
Giovambattista De Sarro

2 December 2011 in Epilepsia
Verified
Journal Article
Closed access
PDF file
CLChiara Luoni
Chiara Luoni
Francesca BisulliFrancesca Bisulli
Francesca Bisulli
MCMaria Paola Canevini
Maria Paola Canevini
GSGiovambattista De Sarro
Giovambattista De Sarro
CFCinzia Fattore
Cinzia Fattore
OGon behalf of the SOPHIE Study Group
on behalf of the SOPHIE Study Group

1 July 2000 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SGSilvana Grasso
Silvana Grasso
GSGiovambattista De Sarro
Giovambattista De Sarro
ASAngela De Sarro
Angela De Sarro
Nicola MICALENicola MICALE
Nicola MICALE
MZMaria Zappalà
Maria Zappalà
CMCarlo De Micheli
Carlo De Micheli

1 March 2001 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
ASAngela Sarro
Angela Sarro
GSGiovambattista De Sarro
Giovambattista De Sarro
This review focuses on the most recent research findings on adverse reactions caused by quinolone antibiotics. Reactions of the gastrointestinal tract, the central nervous system (CNS) and the skin are the most often observed adverse effects. Occasionally major events such as phototoxicity, cardiotoxicity, arthropathy and tendinitis occurr, leading to significant tolerability problems. Over the years, several structure-activity and side-effect relationships have been developed, in an effort to improve overall antimicrobial efficacy while reducing undesiderable side-effects. In this article we review the toxicity of fluoroquinolones, including the newer derivatives such levofloxacin, sparfloxacin, graepafloxacin and the 7-azabicyclo derivatives, trovafloxacin and moxifloxacin. A special attention is given to new data on mechanistic aspects, particularly those regarding CNS effects. In recent years extensive in vivo and in vitro experiments have been performed in an attempt to explain the neurotoxic effects of quinolones sometimes observed under therapeutic conditions. However, the molecular target or receptor for such effects is still not exactly known. Several mechanisms are thought to be responsible. The involvement of g-aminobutyric acid (GABA) and excitatory aminoacid (EAA) neurotransmission and the kinetics of quinolones distribution in brain tissue are discussed. In addition, quinolones may interact with other drugs theophylline and nonsteroidal antinflammatory drugs (NSAID s )in producing CNS effects This article provides information about the different mechanisms responsible of quinolones interaction with NSAID s , methylxanthines, warfarin and antiacids.

1 May 2016 in Pharmacological Research
Verified
Journal Article
Closed access
RCRita Citraro
Rita Citraro
ALAntonio Leo
Antonio Leo
ACAndrew Constanti
Andrew Constanti
EREmilio Russo
Emilio Russo
GSGiovambattista De Sarro
Giovambattista De Sarro

22 April 2010 in Epilepsia
Verified
Journal Article
Closed access
PDF file
MCMaria Paola Canevini
Maria Paola Canevini
GSGiovambattista De Sarro
Giovambattista De Sarro
CGCarlo Andrea Galimberti
Carlo Andrea Galimberti
GGGiuliana Gatti
Giuliana Gatti
LLLaura Licchetta
Laura Licchetta
OGon behalf of the SOPHIE Study Group
on behalf of the SOPHIE Study Group